Evaluation of the SIOPEN semi-quantitative scoring system in planar simpatico-adrenal MIBG scintigraphy in children with neuroblastoma

Neoplasma

Volumn 62, Issue 3, 2015, Pages 449-455

  Radovic, B ^a   Artiko, V ^b   Sobic Saranovic, D ^b   Trajkovic, G ^b   Markovic, S ^c   Vujic, D ^b   Obradovic, V ^b  

^a UNIVERSITY OF PRI TINA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Catecholamine; mIBG scintigraphy; MYCN amplification; Neuroblastoma; Score; Semi quantitative

Indexed keywords

(3 IODOBENZYL)GUANIDINE; FERRITIN; HOMOVANILLIC ACID; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE; VANILMANDELIC ACID;

ARTICLE; CANCER STAGING; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEWBORN; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; SCINTIGRAPHY; SCORING SYSTEM; SIOPEN SCORING SYSTEM;

EID: 84969611117     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_053     Document Type: Article

References (33)

1. KAATSCH P Epidemiology of childhood cancer. Cancer Treat Rev 2010; 36: 277-85. http: //dx. doi. Org/10. 1016/j. ctrv. 2010. 02. 003
2. BERTHOLD E SIMON T Clinical presentation, In: Cheung NK, Cohn S, editors. Neuroblastoma, Springer-Verlag Berlin Heidelberg 2005; 63-85
3. SHIMADA H, NAKAGAWA A Pathology of the Peripheral Neuroblastic Tumors. Lab Med 2006; 37: 684-689. http: // dx. doi. org/10. 1309/0506ClBM8GBVV224
4. ADY N, ZUCKER JM, ASSELAIN B, EDELINE V, BONNIN F et al. A new 1231-MIBG whole body scan scoring method-Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A: 256-261. http: //dx. doi. org/10. 1016/0959-8049(94)00509-4
5. MESSINA JA, CHENG SC, FRANC BL, CHARRON M, SHULKIN B et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006; 47: 865-74. http: //dx. doi. org/10. 1002/pbc. 20777
6. LEWINGTON V, BAR-SEVER Z, LYNCH T, MCEWAN AJB, GIAMMARILE F et al. Development of a semi-quantitative mIBG reporting method system. Pediatr Blood Cancer 2011; 53: 808
7. HRNBLl-ESIOP_protocol_anglais_amendement4_juillet2009. pdf http: //www. oncauvergne. fr/index. php?option=com_ docman&task=doc_download&gid=9288dtemid
8. RILEY RD, HENEY D, JONES DR, SUTTON AJ, LAMBERT PC et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004; 10: 4-12. http: //dx. doi. org/10. 1158/1078-0432. CCR-1051-2
9. OLIVIER P, COLARINHA P, FETTICH J, FISCHER S, FROKIER J et al. Guidelines for radioionated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003; 30: B45-50. http: //dx. doi. org/10. 1007/s00259-003-1138-9
10. http: //www. eanm. org/docs/dosagecard. pdf
11. MATTHAY KK, SHULKIN B, LADENSTEIN R, MICHON J, GIAMMARILE F et al. Criteria for evaluation of disease extent by 1231-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. B J Cancer 2010; 102: 1319-1326. http: // dx. doi. org/10. 1038/si. bic. 6605621
12. SCHROEDER H, WACHER J, LARSSON H, ROSTHOEJ S, RECHNITZER C PETERSEN BL et al. Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981-2000: a population-based study. Br J Cancer 2009; 100: 853-7. http: //dx. doi. org/10. 1038/ si. bic. 6604922
13. BERNSTEIN ML, LECLERC JM, BUNIN G, BRISSON L, ROBISON L et al. A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 1992; 10: 323-329
14. NAVALKELE P, O'DORISIO MS, O'DORISIO TM, ZAMBA GK, LYNCH CF Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer 2011; 56: 50-57. http: //dx. doi. org/10. 1002/ pbc. 22559
15. PEREL Y, CONWAY J, KLETZEL M, GOLDMAN J, WEISS S et al. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. Pediatr Hematol Oncol 1999 Jan-Feb; 21: 13-8. http: //dx. doi. org/10. 1097/00043426-199901000-00004
16. FRAPPAZ D, COMBARET V, DESUZINGES C, BOUFFET E, BAILLY C et al. Can MIBG scan replace the need for bone marrow assessment at diagnosis and reassessment in stage 4 neuroblastomas? Bull Cancer 2004; 91: E253-60.
17. ERDELYI DJ, ELLIOT M, PHILLIPS B Urine catecholamines in pediatrics. Arch Dis Child Educ Pract Ed 2011; 96: 107-111. http: //dx. doi. org/10. 1136/adc. 2010. 207126
18. BERTHOLD F, HUNNEMAN DH, HARMS D, KÄSER H, ZIESCHANG J Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localized but not with metastatic neuroblastoma. Eur J Cancer 1992; 28: 1950-1954. http: //dx. doi. org/10. 1016/0959-8049-(92)90234-S
19. SIMON T, HERO B, HINNEMAND H, BERTHOLD F Tumor marker are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 2003; 39: 1899-1903 http: //dx. doi. org/10. 1016/S0959-8049(03)00376-9
20. MAUREA S, LASTORIA S, CARACO C, INDOLFI P, CASLE F et al. Iodine-131 MIBG imaging to monitor chemotherapy response in advanced neuroblastoma: comparison with laboratory analysis. J Nucl Med 1994; 35: 1429-1435.
21. IZBICKI T, IZBICKA E, MAZUR J Prognostic significance of biochemical heterogeneity of catecholaminergic clones in neuroblastoma. J Pediatr Surg 2006; 41: 1506-15012. http: // dx. doi. org/10. 1016/j. jpedsurg. 2006. 05. 057
22. STRENGER V, KERBL R, DORNBUSCH HJ, LADENSTEIN R, AMBROS PF et al. Diagnostic andprognostic impact ofurinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 2007; 48: 504-509. http: //dx. doi. org/10. 1002/pbc. 20888
23. AYDIN GB, KUTLUK MT, YALCIN B, VARAN A, AKYUZ C et al. The prognostic significance of vanillylmandellic acid in neuroblastoma. Pediatr Hematol Oncol 2010; 27: 435-48. http: //dx. doi. org/10. 3109/08880018. 2010. 489932
24. OSMANAGAOGLU K, LIPPENS M, BENOIT Y, OBRIE E, SCHELSTRAETE K et al. A comparison of iodine-123 metaiodobenzylguanidine scintigraphy and single bone marrow aspiration biopsy in the diagnosis and follow-up of 26 children with neuroblastoma. Eur J Nucl Med 1993; 20: 1154-60. http: // dx. doi. org/10. 1007/BF00171013
25. IEHARA, T, HOSOI H, AKAZAWA K, MATSUMOTO Y, YAMAMOTO K, et al. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br J Cancer 2006; 94: 1510-1515. http: // dx. doi. org/10. 1038/si. bic. 6603149
26. SPITZA R, HERO B, SKOWRON M, ERNESTUS K, BERTHOLD B et al. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification Eur J Cancer 2004; 40: 2753-2759. http: // dx. doi. org/10. 1016/j. ejca. 2004. 05. 002
27. MORA J, GERALD WL, CHEUNG NKV. Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett 2003; 97: 119-124. http: //dx. doi. org/10. 1016/S0304-3835(03)00094-6
28. ZELTZER PM, MARANGOS PJ, EVANS AE, SCHNEIDER SL Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course. Cancer 1986; 57: 1230-4. http: //dx. doi. org/10. 1002/1097-Q142-(19860315)57: 6<1230:: AID-CNCR2820570628>3. 0. CQ; 2-#
29. MASSARON S, SEREGNI E, LUKSCH R, CASANOVA M, BOTTI C et al. Neuron-specific enolase evaluation in patients with neuroblastoma. Tumor Biol 1998; 19: 261-8. http: // dx. doi. org/10. 1159/000030016
30. CANGEMI G, REGGIARDO G, BARCO S, BARBAGALLO L, CONTE M et al. Prognostic value of ferritin, neuron-specif-ic enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. Onco Targets Ther 2012; 5: 417-423.
31. DECAROLIS B, SCHNEIDER C, HERO B, SIMON T, VOLLAND R et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol 2013; 31: 944-51. http: // dx. doi. org/10. 1200/JCO. 2012. 45. 8794
32. 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Childrens Oncology Group. Pediatr Blood Cancer 2011; 56: 1041-1045. http: //dx. doi. org/10. 1002/pbc. 22991
33. DUBOIS SG, KALIKA Y, LUKENS JN, BRODEUR GM, SEEGER RC et al: Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21: 181-189. http: //dx. doi. org/10. 1097/00043426-199905000-00005